Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Yi Cai

Pain Medicine La Jolla, CA Medical Doctor

NPI 1497142293 CMS profile 1372447

9400 Campus Point Dr, La Jolla, CA 92093

Open in the dashboard

General payments

$22,349

133 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Yi Cai of La Jolla, CA is reported in the CMS Open Payments database as having received $22,349 across 133 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $122 4
2024 General $110 4
2023 General $382 9
2022 General $418 10
2021 General $2,048 29
2020 General $1,983 40
2019 General $17,286 37

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Yi Cai
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to Yi Cai were reported at $122. Among 2,779 Pain Medicine profiles paid that year, the median was $458 and the middle half received between $124 and $1,401.

Show as a table
Year Yi Cai Pain Medicine median Middle half National median
2019 $17,286 $498 $126–$1,682 $163
2020 $1,983 $284 $80–$910 $114
2021 $2,048 $399 $112–$1,219 $132
2022 $418 $455 $137–$1,484 $149
2023 $382 $484 $128–$1,495 $160
2024 $110 $498 $131–$1,540 $164
2025 $122 $458 $124–$1,401 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $16,884 22 payments
  2. Abbott Laboratories $3,370 57 payments
  3. Nevro Corp. $652 16 payments
  4. Medtronic USA, Inc. $283 13 payments
  5. SI-BONE, Inc. $259 2 payments
  6. Relievant Medsystems, Inc. $207 2 payments
  7. GRT US Holding, Inc. $154 3 payments
  8. MML US, Inc. $137 1 payment
  9. Painteq LLC $85 3 payments
  10. SPR Therapeutics, Inc $78 2 payments
  11. Other $241 12 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Grant $15,000 1 payment
  2. Food and Beverage $6,346 125 payments
  3. Travel and Lodging $929 6 payments
  4. Education $74 1 payment
Products named General payments · program years 2019–2025
  1. SPECTRA WAVEWRITER $15,813 4 payments
  2. Proclaim Family of SCS IPGs $2,013 34 payments
  3. Proclaim IPG $997 14 payments
  4. Senza Spinal Cord Stimulation System $636 15 payments
  5. WAVEWRITER ALPHA $433 5 payments
  6. GENERAL PAIN MANAGEMENT $260 3 payments
  7. Intracept Pain $207 2 payments
  8. Intracept Pain $207 2 payments
  9. INTELLIS $163 6 payments
  10. PROCLAIM $158 3 payments
  11. Other $1,652 55 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

263

Median for Interventional Pain Management: 1,220

Drug cost

$6,127

Median for Interventional Pain Management: $39,344

Branded share of claims

29.7%

Median for Interventional Pain Management: 34.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gabapentin Generic 105 $2,682
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 46 $930
Pregabalin Generic 31 $855
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 32 $765
Tizanidine Hcl Generic 37 $561
Celecoxib Generic 12 $334

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,476 Part D prescribers listed as Interventional Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 43 billing codes

Paid by Medicare

$99,292

Of which drugs: $12,153

Medicare patients

153

Average age 74

Services billed

3,712

104 women, 49 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 33%
Depression 29%
Diabetes 27%
Heart failure 24%
Osteoporosis 22%
COPD 21%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 30 252 $192

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

133 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record